SFEBES2025 Poster Presentations Late Breaking (68 abstracts)
Dalbavancin reduces healing times and hospital inpatient stay for patients with diabetic foot osteomyelitis
Benái Paponette , Avril Clancy , Emily Madden , Peter Lynch , Carol Doherty , Elias Eltoum , Joseph Kelly , Fatima Alidrous , Georgjis Moisejevs , Vlasta Zujicatalic , Ana Rueda-Benito , Siobhan Bacon & Catherine McHugh
Sligo University Hospital, Sligo, Ireland
Diabetic foot osteomyelitis (DFO) poses great clinical challenges due to prolonged treatment with antimicrobial therapy. Dalbavancin is a new lipoglycopeptide antimicrobial that has shown great potential in treatment of osteomyelitis. With a two-dosing regimen on day 1 and day 8, dalbavancin cortical bone concentration lasts 8 weeks demonstrating great bone exposure. This single centre, retrospective, observational analysis aimed to assess resolution of infection and healing outcomes in patients with DFO and soft tissue infection. Patients who received two doses of intravenous dalbavancin as an outpatient were compared to a similar cohort who received a prolonged inpatient course of alternative antibiotics (intravenous or oral) prior to dalbavancin availability. Adult patients (60-95 years) presenting with DFO susceptible to Staphylococcus Aureus in Sligo University Hospital from 2016 were eligible for enrolment in the control group. The control group consisted of those who received a prolonged course of inpatient antibiotic therapy prior to dalbavancin’s availability. They were compared to those who received two doses of intravenous dalbavancin as an outpatient. In total 82 patients were identified for inclusion. (58 patients treated with dalbavancin and 24 patients treated with alternative intravenous antibiotics). After exclusion, 44 patients were deemed eligible for analysis in the primary group and 20 patients were deemed eligible in the control group. Healing was achieved between the two groups with no significant difference (P=0.293). Of those who achieved healing, there was a significant difference in healing times between patients receiving two courses of intravenous dalbavancin versus a prolonged course of alternative intravenous antibiotics (P=0.038). Healing occurred within 97 ±113.7 days in the primary group compared to172 ±119.8 days in the control group. Results of this research suggests that dalbavancin use in DFO reduces healing times when compared to alternative intravenous antibiotics resulting in reduction of inpatient length of stay.
Volume 109
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more